Promising malaria vaccine moves closer to protecting young children
NCT ID NCT05155579
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times
Summary
This study tested the safety and immune response of the R21/Matrix-M malaria vaccine in 594 children aged 5 to 36 months in Mali. Researchers compared different vaccine formats and schedules, and checked if it could be given safely alongside routine childhood vaccines. The goal is to develop an effective malaria vaccine for young children in Africa.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CCVTM, University of Oxford
Oxford, United Kingdom
-
Malaria Research & Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences Techniques and Technologies of Bamako
Bamako, Mali
Conditions
Explore the condition pages connected to this study.